Myelodysplastic syndromes (MDS) are relatively rare (4 new cases per 100000 persons per year) diseases of the older population mainly presenting with anemia and cytopenia and frequently progressing to acute myeloid leukemia (AML).
- 12,000 people in the USA diagnosed annually with MDS
- 4 new cases per 100,000 persons per year
- 80% to 90% of people who develop MDS are older than 60 years of age.
- Death from MDS is often caused by bleeding and infection from low blood cell counts and if the MDS progresses to AML (acute myelogenous leukemia)
- About one third of patients with MDS develop AML
Approved treatments for MDS
Three agents have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of MDS:
- Vidaza: 5-azacytidine
- Dacogen: Decitabine
- Revlimid: Lenalidomide